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Clinical guidelines exist for the treatment of chronic epilepsy and epilepsy in women2. This publication provides guidance for
the clinician investigating and managing epilepsy in adults who have an intellectual disability as defined by an Intelligence
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INTRODUCTION
Studies suggest that as many as one fifth of the pop-
ulation of people with intellectual disabilities across
the lifespan have epilepsy3. Higher prevalence figures
are quoted in institutional settings and with decreasing
IQ4–6.
Uncontrolled seizures have a profound impact on
the quality of life of individuals and carers alike7–11.
Furthermore, the management of epilepsy in people
with an intellectual disability provides special chal-
lenges. Key factors in this include the aetiology and
severity of the epilepsy, a limited evidence base for in-
terventions and difficulties in investigation and com-
munication.
Guidelines exist for the management of epilepsy in
the general population1 and for women with epilepsy2.
Specific guidelines for the management of epilepsy in
the intellectually disabled are not available. In recog-
nition of this, the special interest research group for
health of the International Association for the Scien-
tific Study of Intellectual Disability (IASSID) created
a working group to establish guidelines for the man-
agement of epilepsy in this population.
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GUIDELINE DEVELOPMENT GROUP
This multiprofessional international group included
clinical psychologists, clinical neurophysiologists, in-
tellectual disability nurses, neurologists, paediatric
neurologists, neuropsychiatrists, intellectual disability
psychiatrists and representatives of carer groups.
SCOPE OF THE GUIDELINES
These guidelines have been developed taking into ac-
count the individual characteristics of the person with
epilepsy, difficulties in diagnostic investigations and
the lack of controlled trials in intellectual disabil-
ity during drug development. Through consultation,
a consensus view on the management of epilepsy in
adults with an intellectual disability has been achieved.
In order to recognize the multiprofessional nature of
care for the disabled group the guidelines could be ap-
plicable to both clinicians and service providers.
EVIDENCE REVIEW AND SYNTHESIS
Medline and Psychlit searches were performed on
epilepsy and intellectual disability, mental handicap
and mental retardation (please refer to Appendix 1).
Additional references were followed up from individ-
ual papers. Key intellectual disability journals were
also hand searched for relevant articles. Additional in-
formation was sourced from the guideline develop-
ment group.
As will be seen there are major gaps in the evidence
base for this field. Where these gaps were recognized,
consensus group opinion was sought.
Levels of evidence
In the following text, statements and recommendations
are made. In the case of interventional studies these
are assigned a level of evidence based on a recog-
nized evidence classification system12. Recommenda-
tions were characterized according to their strength on
the same framework. In addition, the panel recognized
the paucity of studies directly performed on samples
of individuals from adult intellectual disability popu-
lations. Therefore, each level of evidence and recom-
mendation is graded according to the sample popula-
tion from which the data was derived. These are de-
scribed in Table 1.
Table 1: Scheme for grading strength of evidence and
recommendations.
Levels of evidence
1 Well designed randomized
controlled trials, meta-analyses or
systematic reviews
2 Well designed cohort or case
control studies
3 Uncontrolled studies or consensus
Grading of recommendations
A Directly based on level 1 evidence
B Directly based on level 2 or
extrapolated recommendation from
level 1 evidence
C Directly based on level 3 or
extrapolated recommendation from
level 2 evidence
Sample population
S1 Adult intellectual disability sample
S2 Paediatric intellectual disability
sample
S3 Mixed intellectual disability
sample
S4 Non-intellectual disability sample
THE INDIVIDUAL
Characteristics of the individual with an intellec-
tual disability will impact on the diagnostic process,
assessment and the implementation of management
plans. Factors that would make management difficult
include:
(1) The aetiology of the intellectual disability.
(2) The severity of the intellectual disability.
(3) Psychiatric and behavioural problems.
(4) Recognized and unrecognized physical health
problems.
(5) Swallowing and feeding difficulties.
(6) Communication difficulties and the individual’s
ability to understand the treatment.
(7) The capacity to make an informed choice.
Aetiology
The aetiology of the intellectual disability may high-
light characteristics of the epilepsy including the
seizure type. This is thought to be the case in some
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genetically determined conditions associated with in-
tellectual disability; for example, in Angelman’s syn-
drome the seizure type is believed to be of a crypto-
genic generalized nature13 and in the Fragile X syn-
drome features similar to benign epilepsy with cen-
trotemporal spikes may be seen14.
Severity
An assessment of the individual’s level of ability
can be an important guide to the likely severity of
the epilepsy and a pointer to other comorbid fea-
tures5, 15. When assessing severity the clinician should
not overlook the possibility that the individual has a
state-dependent learning disability where the severity
of the apparent learning disorder has been complicated
by the frequency of the seizures or, in some cases,
by the presence of unrecognized non-convulsive sta-
tus epilepticus.
Psychiatric and behavioural problems
Studies have found rates of behaviour disturbance and
psychiatric disorder to be significantly higher in peo-
ple with intellectual disabilities than in the general
population16–19. It is less clear as to whether this is due
to their epilepsy or whether the presence of epilepsy
is merely a marker for increased behavioural or psy-
chiatric morbidity in the intellectually disabled pop-
ulation20. In clinical practice however there will fre-
quently be concerns that:
(1) A behavioural disturbance may be a manifesta-
tion of epilepsy.
(2) Epilepsy treatment may worsen an existing be-
havioural problem.
(3) A behavioural problem may be caused by the
epilepsy treatment.
(4) The interaction between antiepileptic medica-
tion and psychiatric treatments.
Physical health problems
Up to one third of people with an intellectual dis-
ability have an associated physical disability, most of-
ten cerebral palsy. This may put them at risk of in-
jury during seizures (particularly dislocation). Swal-
lowing and feeding difficulties are also common and
are associated with gastro-oesophageal reflux, an im-
portant consideration when choosing the preparation
of antiepileptic medication. Many individuals with an
intellectual disability often have unrecognized physi-
cal morbidity21. Hearing and vision are two problem
areas frequently overlooked, up to one third have poor
eyesight and 40% have a problem with hearing. These
two problems increase with increasing age and may
also lead to difficulties in drug administration. Phys-
ical disabilities are an important consideration when
formulating a treatment plan as they may act as a
marker of potential early mortality.
Communication and capacity
Some degree of difficulty with communication is in-
evitable in an individual with an intellectual disability.
Difficulties with communication can lead to difficul-
ties in history taking and examination22, 23. Many in-
dividuals with an intellectual disability will be hand-
icapped by their communication difficulties and will
be unable to take an active part in the decision-making
process. It is important to note the capacity each in-
dividual has to make decisions about their treatment.
Where they are unable to participate in the decision-
making process they should not be penalized by this,
but should have access to the most appropriate treat-
ment for their epilepsy.
The individual—statements and recommendations.
• Any individual being assessed for the presence of
epilepsy or being treated for epilepsy should have
a comprehensive evaluation of their current abili-
tites, health status and presence of co-morbidity.
• Any individual being assessed for the presence of
epilepsy or being treated for epilepsy should have a
recording of any current psychiatric or behavioural
problem.
• Any individual being assessed for the presence of
epilepsy or being treated for epilepsy should have
an assessment of their ability to understand and
communicate and their capacity to make informed
choice.
INVESTIGATIONS
The core investigation in the diagnosis of epilepsy in a
patient with an intellectual disability is, as in the gen-
eral population, the clinical history—with an emphasis
on witness description of seizure. The hallmark of the
epileptic phenomenon is the paroxysmal nature of the
disorder—brief, episodic changes should be described.
However, the special characteristics of this population
make the gathering and interpretation of these data
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more complex. In particular, the communicative abili-
ties of the individual may make the recognition of aura
and post-ictal phenomena difficult. Furthermore, diag-
nostic overshadowing is common and an expectation
for either behaviour or seizure disorder may influence
the objectivity of both carers and professionals when
reporting events.
A particularly difficult issue arises over the differen-
tial diagnosis of behaviour and epilepsy. It is possible
that the clinician may be called upon to assess whether
behavioural outbursts or repetitive manneristic move-
ments have an epileptic basis; this is complicated by
the high frequency of behaviour problems and man-
nerisms in this population24–26. As many as 20–25%
of patients referred to a specialist epilepsy unit have a
misdiagnosis of epilepsy.
Syncope, non-epileptic seizures, panic attacks, hal-
lucinations and movement disorders may be mistaken
for seizures but may also coexist in an individual diag-
nosed with epilepsy. When evaluating an individual’s
epilepsy the possibility of alternative explanations for
these events should be considered.
Clear unbiased reporting is essential and carers
may need education in performing and in describing
their observations. Behavioural descriptions of seizure
events, written by such eyewitnesses, are essential in
clinical practice, both to aid the clinician in diagno-
sis and for accurate tracking of seizure frequency27.
These behavioural descriptions should be entered in
seizure diaries, which should be kept with the individ-
uals at all times. This is important since the majority
of people with intellectual disabilities have multiple
carers across a range of care settings. Video recording
of events may further aid diagnosis28. In cases of be-
havioural outbursts a functional analysis of behaviour
may also help in differentiating a behaviour from a
seizure.
As in the general population with epilepsy, elec-
troencephalography (EEG) may aid in seizure and
seizure syndrome diagnosis. Video EEG and teleme-
try remain important diagnostic tools for the individual
with intellectual disability, however these may not be
readily available. Some abnormal movements in peo-
ple with epilepsy may mimic seizures but on video
EEG these have been demonstrated to be non-seizure
related29. Observed behaviour may be attributed to
epilepsy, particularly in the severely or profoundly
disabled patient. Staring and abnormal motor activity
have often been reported as epileptic activity which,
on subsequent video EEG, has been demonstrated to
be non-epileptic 60% of the time30, 31. The EEG may
be of particular value in those with chronic epilepsy,
where despite adequate treatment, individuals are still
suffering regular seizure-like movements.
There is a high prevalence of abnormality found
on neuroimaging and in particular magnetic resonance
imaging (MRI)32. Patients with intellectual disabilities
may have difficulties co-operating with the technicians
in the MRI suite and may, therefore, need sedation or
generalized anaesthesia.
Investigations—recommendations and statements.
• Individuals with an intellectual disability should
have access to the full range of electrophysiologi-
cal and neuroimaging investigations.
• Facilities should be available for imaging under
general anaesthesia.
• Where doubt exists as to the diagnosis of a be-
havioural outburst, video recording and functional
analysis of behaviour is recommended prior to
treatment.
SEIZURE AND SYNDROME DIAGNOSIS
The identification of both seizure type and seizure syn-
drome has implications for therapeutic interventions
and prognosis. Individuals with an intellectual disabil-
ity are particularly likely to have associated syndromal
diagnosis such as the Lennox–Gastaut syndrome, in-
fantile myoclonic epilepsies33 or have suffered from
infantile spasms (Trevathan et al.34).
The guidelines for the treatment of the severe
epilepsy syndromes of childhood such as West syn-
drome, Laundau Kleffner syndrome, CSWS (con-
tinuous spike-wave discharges during slow wave
sleep) syndrome, Rasmussen syndrome, early my-
oclonic encephalopathy and early infantile epileptic
encephalopathy or Ohtohara syndrome are not in-
cluded in this paper due to the focus on adulthood.
These are under analysis to be reported later.
Seizure and syndrome diagnosis—recommendations
and statements.
• All individuals should have, where possible,
seizure type and syndrome classified as per the
ILAE classification.
TREATMENT HISTORY
Health professionals caring for patients with an intel-
lectual disability commonly complain that insufficient
data exist on the individual’s past history21. This may
be related to the communication difficulties of the in-
dividual and the need for information to come from
carers. This is often exacerbated if an individual has
had many changes in accommodation or if different
carers attend each appointment. Past response to med-
ication should also be available to the clinician as this
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may guide treatment choice, interpretation of side ef-
fects and assessment of the severity of the individual’s
epilepsy.
Treatment history—recommendations and statements.
• All patients with epilepsy and intellectual disabil-
ity should have available full treatment histories
for clinical consultation.
Table 2: Articles that include intellectual disability and
epilepsy.
Paper Level of evidence Sample
The felbamate study 1 2
group on Lennox–Gastaut (1.1) (2.3)
syndrome. (1993)50
Motte et al.51 1 2
(1.1) (2.4)
Sachdeo et al.52 1 3
(1.3) (2.7)
Crawford et al.53 1 1
(0) (0)
Kaski et al.54 1 2
(1.42) (2.5)
Siegel et al.55 2 2
(1.57) (2.3)
Pitkanen et al.56 2 1
(2) (1.14)
Matilainen et al.57 2 2
(2.1) (1.57)
Linuma et al.58 2 2
(2.14) (2.4)
Gaily et al.59 2 2
(2.4) (2)
Mikati et al.60 3 3
(2.7) (2.8)
McCusker et al.61 3 2
(2.7) (1.86)
Scheepers et al.62 3 1
(2.7) (1)
Bhaumik et al.63 3 1
(2.57) (1.4)
Buchanan64 3 2
(2.9) (2.4)
Numbers in parentheses is the mean score of Guideline Group.
THE CARE CONTEXT
A great diversity exists as to the care context of in-
dividuals with epilepsy and intellectual disability. In-
dividuals may live alone with support, be cared for
at home by relatives, be in community-based group
homes or reside in institutions. Evidence from the
broader research on intellectual disability would sug-
gest that the care setting is important in behavioural
disorders35–37. Furthermore, training levels and stan-
dards in residential settings will impact on the out-
come of some medical interventions such as attempted
medication reduction in individuals on psychotropic
medication38.
In addition, carer knowledge and the level of staff
support may impact on their ability to follow through
epilepsy-related interventions. This may be particu-
larly true when rectal diazepam is indicated for pro-
longed seizures. The Epilepsy Knowledge Profile may
be a useful tool for the appraisal of carers’ knowledge
about both social and medical aspects of epilepsy39.
The care context—statements and recommendations.
• An assessment of the individual’s level of sup-
port, and the ability of that support to work with
epilepsy management plans should be assessed in
all individuals with epilepsy and intellectual dis-
ability.
ASSESSING THE IMPACT OF EPILEPSY
Epilepsy may profoundly affect the lives of patients
through effects on cognition40, falls and fractures41,
hospitalization42 and increased mortality43–46. Un-
published research also suggests carers may also be
affected through an increased carer burden47.
Establishing a baseline for the current impact of
epilepsy will be a composite of measures covering:
(a) Seizure frequency.
(b) Injury and hospitalization.
(c) Broader quality of life measures.
Increasing research into these broader issues has led to
the development of scales designed to measure carer,
staff and patient views11, 48.
The impact of epilepsy—recommendations and stan-
dards.
• A full assessment of how epilepsy is affecting an
individual should be undertaken before manage-
ment change is initiated. The assessment should
include evidence of impact on cognitive function-
ing and physical health.
• An assessment of the impact of epilepsy on the
family or carers should be carried out, using where
possible appropriate validated measures.
TREATMENT OPTIONS
Guidelines already exist as to the management of
epilepsy in adults without intellectual disability1.
Meta-analysis of trial data has failed to show signif-
icant differences between compounds in add-on situ-
ations49. This section will address the use of anticon-
vulsants in clinical situations:
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(1) Treatment of generalized seizures (absence,
primary generalized tonic–clonic, myoclonic
seizures).
(2) Management of Lennox–Gastaut syndrome.
(3) Treatment of partial seizures (simple, complex,
with or without secondary generalization).
(4) Treatment of prolonged or cluster seizures.
The guidelines group assessed all the known pub-
lished and one unpublished study of interventions in
adults with intellectual disability and epilepsy. Table 2
shows these studies and the mean ratings for the level
of evidence provided by the group. These data will be
incorporated into the recommendations.
DRUG TREATMENT
Principles of drug therapy
• Ensure that the patient has received appropriate
first-line treatment for their seizure type and syn-
drome.
• In patients still continuing to have seizures, despite
appropriate first-line antiepileptic treatment:
– review diagnosis
– review treatment adherence
– ensure that the maximum tolerated dose has
been used
∗ If the first drug continues to be ineffective
at the maximum tolerated dose, an alterna-
tive drug should be introduced slowly with-
out tapering the first. If the patient has a
good response to the second drug consider
withdrawing the first drug gradually.
∗ If reasonable options for monotherapy
have been explored and acceptable symp-
tom control is still not achieved, long-term
two-drug therapy should be tried.
∗ If the first add-on drug is not effective,
replace with a second add-on drug then
slowly withdraw the ineffective drug. This
process can be repeated for other possible
add-on drugs.
∗ If symptoms are still not controlled on two
drugs, some patients may benefit from an
additional third drug.
∗ Intermittent treatment with benzodi-
azepines such as clobazam or clonazepam
may be useful in preventing clustering of
seizures, or on days when seizures need
particularly to be avoided. Used intermit-
tently the risk of developing tolerance to
the drug is reduced.
TREATMENT OF GENERALIZED SEIZURES
(ABSENCE, PRIMARY GENERALISED
TONIC–CLONIC, MYOCLONIC SEIZURES)
There is a paucity of monotherapy data in patients with
generalized epilepsy. The grading of our recommenda-
tions reflects this situation.
Recommended first line
• Sodium valproate, lamotrigine (C, S4).
If first line is unsuccessful or unacceptable side
effects
• Topiramate (C, S4).
• Carbamazepine (C, S4) (where no myoclonic or
absence seizures are present).
Long term benzodiazepine use in adults with an intel-
lectual handicap should only occur when other mea-
sures have been attempted. There are specific concerns
over excessive sedation with cognitive effects, move-
ment disorders, hypersalivation and seizures on drug
withdrawal (C).
THE LENNOX–GASTAUT SYNDROME
• Lamotrigine, topiramate and felbamate can reduce
atonic seizures as add-on therapy in individuals
with Lennox–Gastaut syndrome (A, S4).
Lamotrigine has been shown to be effective in all
seizure types associated with the Lennox–Gastaut
syndrome. (A, S4).
TREATMENT OF PARTIAL SEIZURES
(SIMPLE, COMPLEX, WITH OR WITHOUT
SECONDARY GENERALIZATION)
Recommended first line
• Valproate, carbamazepine and lamotrigine (C, S4).
• The differential cognitive profile of lamotrigine
when compared with carbamazepine may give
lamotrigine an advantage in those with cognitive
deficits (C, S4).
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Whilst having comparative efficacy the use of
phenytoin and phenobarbitone are not recommended
due to their cognitive and behavioural side effects, and
in the case of phenytoin the complex saturation kinet-
ics (C, S4).
RECOMMENDED ADD-ON THERAPY
There is a dearth of evidence comparing drugs in the
add-on partial epilepsy situation. A meta-analysis of
add-on studies failed to differentiate between vigaba-
trin, lamotrigine, gabapentin, topiramate and tiagabine
(A, S4). The novel antepileptic drug levetiracetam has
also shown efficacy in add-on partial seizures. The
recent evidence of visual field deficit in individuals
on vigabatrin means that the use of this drug will be
severely curtailed in the adult population65.
As a matter of good practice the decision should be
based on the relative merits of the drug for the individ-
ual concerned: this will frequently lead to decisions
made on side effect profiles.
DRUG MONITORING
Serum level monitoring of antiepileptic medication
should not be performed without a clear indication.
The main indications are:
• To detect or confirm treatment adherence.
• To adjust phenytoin dose.
• To avoid or identify drug-related toxicity.
• Where pharmacokinetic interactions may alter
serum concentrations in unpredictable ways.
TREATMENT OF PROLONGED AND CLUSTER
SEIZURES
An issue of particular importance to clinicians is the
assessment of appropriate acute seizure treatment.
Good evidence exists for the use of diazepam by the
oral or rectal route and some evidence is appearing for
the use of buccal66 or intranasal midazolam62. Due
to the varied care arrangements for people with an
intellectual disability a structured plan for the admin-
istration of such rescue medication is essential.
Treatment of prolonged and clustered seizures—
Statements and recommendations.
• Any individual who has epilepsy and intellec-
tual disability should have an assessment of the
management of prolonged seizures and/or cluster
seizures.
• Where rescue medication is prescribed a care plan
should be completed which must include clear
guidelines on seizure duration, type and maximum
daily dosage.
STANDARDS FOR SERVICES
Many individuals with an intellectual disability and
epilepsy will have carers (both formal and informal)
who support them. Care plans should be individualised
and take account of the following.
Standards for services—recommendations and state-
ments.
In particular services must ensure that:
• Both the medical and psychosocial impact of
epilepsy is adequately assessed, and regularly re-
viewed.
• Carers and staff working with the individual
should receive training in epilepsy and its manage-
ment, and on the impact it has on peoples lives.
• Training should also be provided on methods of
behavioural observation and seizure reporting.
• Carers should also be trained in any necessary
emergency procedures, such as the administration
of rectal medication and resuscitation, and clear
policies should be provided for these on an indi-
vidual basis.
• Care plans should ensure consistency in the sup-
port offered to people with intellectual disabil-
ity and epilepsy. For example, the same individu-
als should accompany the person with epilepsy to
clinic appointments.
• Accurate records should be kept, using seizure di-
aries or equivalents and those working with the
person with epilepsy should be familiar with their
use.
RISK ASSESSMENT
People with epilepsy living in various care settings
will all be put at some level of risk due to their seizure
disorder. The level of risk will depend upon each indi-
vidual, the severity of their epilepsy and the environ-
ment surrounding them at the time of the seizure. It
is important that the level of risk is assessed in order
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reduce the impact of the seizures on the individual’s
quality of life.
Risk assessment—recommendations and statements.
All individuals with epilepsy and intellectual disability
should have a risk assessment covering:
(1) Bathing and showering.
(2) Management of the acute seizure.
(3) Impact of epilepsy in social settings—removing
restrictions.
SUMMARY POINTS
• Epilepsy has a great impact on individuals with
epilepsy and intellectual disability and their fam-
ilies.
• A multiprofessional approach is essential to reduce
this impact.
• Seizure reduction remains the prime aim of
epilepsy management in this population.
• Most intervention decisions are based on non-
intellectual disability studies.
• Those studies that exist are mainly in the Lennox–
Gastaut syndrome.
• The individuals care setting impacts on treatment
application.
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